Brind.

Kodiak Sciences Inc. is developing therapeutics for MESI patients and presented Phase 1b APEX data at scientific meetings in France and Chicago.

4 reports, 1 independent Updated Sep 2
Gone quiet
Reports
4
Developments
3
Repetition
50%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Kodiak Sciences Inc. is developing therapeutics for MESI patients and presented Phase 1b APEX data at scientific meetings in France and Chicago.

Who's involved

What this event is mainly about

How it developed

Newest first. Tap a step to see who reported it.
  1. Tectonic is running the APEX clinical trial.Sub-event
  2. Kodiak presented Phase 1b APEX data on MESI therapeutics at scientific congresses.1 source
  3. Kodiak announced it will present data on its MESI treatment at a congress in Rio de Janeiro.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped
  • PR NewswireKodiak Sciences to Participate in Upcoming Scientific Conferences Highlighting KSI-101 in Patients with Macular Edema Secondary to Inflammation (MESI) PALO ALTO, Calif., Sept. 2, 2025 /PRNewswire/ --
  • PR NewswireKodiak Sciences to Present at American Chemical Society Fall 2025 PALO ALTO, Calif., Aug. 19, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), a precommercial retina focused biotechnology com
  • PR NewswireKodiak Sciences Announces Recent Business Highlights and Second Quarter 2025 Financial Results PALO ALTO, Calif., Aug. 13, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported rece
  • Unknown outlet